期刊文献+

紫杉醇联合卡培他滨在进展期胃癌术前化疗中的应用 被引量:4

原文传递
导出
摘要 目的探讨紫杉醇联合卡培他滨在进展期胃癌术前化疗中的作用。方法回顾分析2009年1月至2011年1月采用紫杉醇联合卡培他滨(XPa方案)行术前化疗的12例进展期胃癌患者的临床病理资料、治疗效果和不良反应。结果全组有效率75.0%(9/12)。手术切除率100%,与术后病理分期比较.50.0%(6/12)分期下降。不良反应主要为脱发,I-Ⅱ度骨髓抑制。术中中位失血量为337.5ml,中位住院时间为22.9d,术后并发症发生率为8.33%(1/12),无手术相关死亡病例。结论进展期胃癌术前采用紫杉醇联合卡培他滨化疗有效而且安全。
出处 《中华胃肠外科杂志》 CAS 北大核心 2011年第10期812-813,共2页 Chinese Journal of Gastrointestinal Surgery
  • 相关文献

参考文献6

  • 1季加孚.胃癌防治新观念.北京:人民军医出版社.2006:34-43.
  • 2张欢,潘自来,宋琦,杜联军,凌华威,丁蓓,陈克敏.多层螺旋CT对胃癌术前TNM分期的诊断价值[J].上海交通大学学报(医学版),2006,26(3):282-287. 被引量:27
  • 3Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer, 2009,12(2) :69-78.
  • 4Okines A, Chau I, Cunningham D. Capecitabine in gastric cancer. Drugs Today (Bare), 2008,44 (8) : 629-640.
  • 5Kang H J, Chang HM, Kim TW, et al. A phase Ⅱ study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer, 2008,98 (2) :316-322.
  • 6张斌,姬社青,陈小兵,金歌,罗素霞,花亚伟,马杰,刘英强.进展期胃癌新辅助化疗疗效及对手术风险影响[J].中华实用诊断与治疗杂志,2011,25(2):162-164. 被引量:18

二级参考文献27

  • 1李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 2Kim D Y, Kim J H, Lee S H, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum- treated patients with advanced gastric cancer[J]. Ann Oncol, 2003,14 (3) : 383-387.
  • 3Wu A W. Xu G W, Wang H Y, et al. Neoadjuvant chemotherapy versus none for resectable gastric cancer[J]. Coehrane Database Syst Rev, 2007,17(4) ;CD005047.
  • 4Fujii M, Kochi M, Takayama T. Neoadjuvant chemotherapy for gastric cancer[J]. Gan To Kagaku Ryoho,2007,34(10):1549- 1552.
  • 5Plukker J T. Mulder N H, Sleijfer D T, et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil[J]. Br J Surg,1991,78(8):955-958.
  • 6Oh S Y, Kwon H C, Lee S, et al. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouraeil (modified FOLFOX-4 ) as first line therapy for gastric cancer patients with malignant ascites[J]. Jpn J Clin Oncol,2007,37(12):930-935.
  • 7Roth A D, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil: docetaxel and cisplatin: and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastriccarcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol, 2007,25 (22) : 3217- 3223.
  • 8Bueno Muino C, Puente Vdzquez J, Sastre Valera J, et al. Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma[J]. Clin Transl Oncol, 2007,9 (5) : 335-338.
  • 9Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer[J]. N Engl J Med,2008,358(1):36-46.
  • 10Kang Y K, Kang W K, Shin D B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase Ⅲ aoninfedority trial[J]. Ann Oncol,2009,20(4):666-673.

共引文献43

同被引文献32

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部